Original Research Article

Inter relationship of plasma lipid profile parameters with plasma uric acid levels in psoriasis

Srinivas S.1, Prashanthkumar Goudappala 2, Kashinath R. T. 3*

1Department of Dermatology, 2Department of Biochemistry, 3Department of Research and Development, Subbaiah Institute of Medical Sciences, NH-13, Purle, Shivamogga, Karnataka, India

Received: 05 May 2018
Revised: 21 May 2018
Accepted: 23 May 2018

*Correspondence:
Dr. Kashinath R. T.,
E-mail: drkashinath_1945@yahoo.co.in

ABSTRACT

Background: Psoriasis is a chronic immune mediated skin disease accompanied with disturbances in systemic lipid turnover. Hyperuricemia has been frequently observed as an additional complication in psoriasis. The relationship between the raised plasma lipid parameters and the uric acid levels in psoriasis need to be ascertained. A study was undertaken to assess the possible relationship of plasma lipid parameters with plasma uric acid levels in psoriasis and to relate any such relationship to psoriasis disease severity.

Methods: Non arthritic psoriasis patients were randomly selected and were grouped into mild (Group 1), moderate (Group 2) as well as severe (Group 3) based on their PASI scores. Plasma lipid parameters and uric acid levels were assessed in these patients.

Results: The results show a significant (p<0.001) parallel raise in plasma uric acid levels along with plasma lipid parameters with the severity of disease in these patients.

Conclusions: A plasma uric acid level along with plasma total cholesterol and triacylglycerol levels fetch much information on the severity of psoriasis disease.

Keywords: Psoriasis, Uric acid, Total cholesterol, Triacylglycerol

INTRODUCTION

Psoriasis is a dermatological syndrome with a population prevalence of 2-3%.1 Its prevalence is affected by genetic, environmental, viral, immunological, biochemical, endocrinological and psychological factors as well as alcohol and drug abuse. It is a common disease affecting approximately about 120-180 million people across the globe. 2 In the recent years psoriasis has been recognised as a systemic disease associated with multi organ abnormalities and complications. 3

Dyslipidemia is one of the principle co-abnormalities seen in psoriatic patients, as generally lipid metabolism and lipid turnover seem to be affected due to an underlying cardiovascular involvement as well as due to underlying psychological stress. It has been shown by many researchers that plasma lipid levels are altered in psoriasis patients.4,19

Uric acid, the end product of purine catabolism in humans, is being implicated and its plasma levels have been shown elevated in inflammatory conditions, in cardiovascular complications and in diabetes mellitus.20,23 Its proportional elevation with plasma cholesterol levels has been observed in diabetic hypercholesterolemia.24 Since the day in 1958, Walkerin, first suggested that psoriasis may be associated with raised plasma uric acid
levels, a few reports are available regarding the uric acid levels in psoriasis patients.25-27

Although the uric acid levels are implicated in psoriasis but the relationship with plasma lipid profile parameters as well as with the severity of the disease is not well established. Hence a study was undertaken to evaluate the plasma uric acid levels in psoriasis patients and to compare these values with the lipid profile parameters.

METHODS

The psoriasis patients attending dermatology outpatient department (OPD) of Subbaiah Institute Medical Hospital and other associated hospitals attached to Subbaiah Institute of Medical Sciences, NH-13, Purale, Shivamogga, were randomly selected. The patients having arthritis complications were excluded from the study. Detailed history, regarding the illness, duration of disease, the drugs taken as well as food habits was collected from these selected psoriasis patients. The normal control subjects were chosen from the employees of Medical College and Medical college hospitals. The present work was carried out during the period August 2017 to January 2018.

A fasting heparinised blood sample (5-7 ml) was collected from both selected psoriasis patients and normal control subjects after obtaining an informed consent. The blood samples were centrifuged at 3500 rpm for ten minutes. The separated plasma was employed for estimation of total cholesterol (TC), triacylglycerols (TAG), HDL cholesterol (HDLC) and uric acid.28-31 VLDL cholesterol (VLDLC) and LDL cholesterol (LDLC) were calculated using the relationships:

a) VLDLC= TC/HDLC
b) LDLC= TC-(VLDLC+HDLC)

detailed history, regarding the illness, duration of disease, the drugs taken as well as food habits was collected from these selected psoriasis patients. The normal control subjects were chosen from the employees of Medical College and Medical college hospitals. The present work was carried out during the period August 2017 to January 2018.

A fasting heparinised blood sample (5-7 ml) was collected from both selected psoriasis patients and normal control subjects after obtaining an informed consent. The blood samples were centrifuged at 3500 rpm for ten minutes. The separated plasma was employed for estimation of total cholesterol (TC), triacylglycerols (TAG), HDL cholesterol (HDLC) and uric acid.28-31 VLDL cholesterol (VLDLC) and LDL cholesterol (LDLC) were calculated using the relationships:

- VLDLC = TC/HDLC
- LDLC = TC - (VLDLC + HDLC)

### Table 1: Showing the grouping of psoriasis patients based on their PASI score.

| Groups               | PASI score |
|----------------------|------------|
| Group-1 (mild psoriasis) | <3         |
| Group-2 (moderate psoriasis) | 3.0-6.0    |
| Group-3 (severe psoriasis)   | >6.1       |

### Table 2: Showing the plasma levels of TC, TAG, VLDLC, LDLC, HDLC and uric acid levels in normal control subjects as well as in psoriasis patients.

| Groups               | TC (mg/dl)     | TAG (mg/dl)   | VLDLC (mg/dl) | HDLC (mg/dl) | LDLC (mg/dl) | Uric acid (mg/dl) |
|----------------------|---------------|--------------|---------------|--------------|--------------|-------------------|
| Normal control subjects (25) | 161.86±31.82 | 114.64±32.21 | 28.35±9.08    | 58.27±8.68   | 104.86±20.28 | 4.69±1.11         |
| Psoriasis subjects (25)    | 214.85±28.12 *** | 247.78±22.16 *** | 50.70±11.12 *** | 45.52±9.38 *** | 123.85±17.28 *** | 8.29±1.61 ***     |

Note: 1: The values expressed are in mean±SD. 2: The number in parenthesis indicates the number of subjects. 3: Probability *p<0.01, **p<0.005 and ***p<0.001.
Table 3: Showing the plasma levels of TC, TAG, VLDLC, LDLC, HDLC as well as plasma uric acid levels in Group-1, Group-2 and in Group-3 psoriasis patients.

| Groups                        | TC (mg/dl) | TAG (mg/dl) | VLDLC (mg/dl) | HDLC (mg/dl) | LDLC (mg/dl) | Uric acid (mg/dl) |
|-------------------------------|------------|-------------|----------------|--------------|--------------|-------------------|
| Group-1 (Mild psoriasis) (04) | 142.68±18.18 | 110.16±22.13 | 20.18±6.16    | 56.16±16.16  | 100.66±21.22 | 4.42±1.16         |
| Group-2 (Moderate psoriasis)(08) | 172.12±14.12*** | 152.26±18.18*** | 36.63±7.12*** | 49.13±15.12*** | 112.12±18.12*** | 6.72±1.31***      |
| Group-3 (Severe psoriasis)(13) | 208.36±20.12*** | 242.16±24.14*** | 49.12±16.18*** | 43.12±16.16*** | 122.8±16.16*** | 8.18±1.81***      |

Note: 1: The values expressed are in mean±SD. 2: The number in parenthesis indicates the number of subjects. 3: Probability *p<0.01, **p<0.005 and ***p<0.001.

Table 3 narrates the plasma levels lipid profile parameters – TC, TAG, VLDLC, LDLC, HDLC and uric acid levels in Group-1, Group-2, Group-3 psoriasis patients. It is evident from the table that the lipid profile parameters except the HDLC are significantly elevated (p<0.001) in Group-3 as compared to Group-1 and Group-2, in Group-2 as compared to Group-1 as well as in Group-3 as compared to Group-2. Further it is evident from the table that there is a parallel elevation in uric acid levels with TC levels as well as with TAG levels in all the three psoriasis groups studied.

DISCUSSION

Generally in inflammatory conditions, various cell signal compounds including the cytokines, the interleukins (IL), tissue necrotic factor (TNF a) and other factors are released by the cells. The raise observed in the present studies, in psoriasis patients, in plasma lipid profile parameters, specifically, the TC and the TAG is in agreement with earlier workers.

The raised plasma levels of lipid parameters in psoriasis may be due to psoriasis-induced inflammation which leads to an increased systemic synthesis of lipids, cholesterol and triacylglycerols because of inflammatory triggered production of cell signalling compounds including the cytokins and the other factors which tends to stimulate the systemic lipid synthesis by inducing Sterol Response Element Binding Protein (SREBP) genes as well as by inducing the genes responsible for HMG CoA reductase enzyme production there by enhancing lipid and cholesterol synthesis, which is essential for the supply of extra lipids and other lipid parameters required for the psoriatic plaque formation. The various lipid transporting protein and related apoproteins synthesis may also boosted in order to transport these lipid components.

Uric acid is a product of the metabolism of purine nucleotides, which are the principle constituents of cellular energy stores, like ATP, and are the components of the nucleic acids, DNA and RNA. In most mammals uric acid is further converted in liver by a liver enzyme uricase to allontoin, thereby reduces the plasma uric acid levels. This enzyme gene in humans is non-functional resulting in normally found uric acid levels in humans. The elevated levels of plasma uric acid observed in inflammatory conditions may be for the compensatory mechanism to counteract raised oxidative stress accompanied with inflammation as uric acid is a known potential antioxidant. Another interesting point regarding inflammation is, the inflammatory conditions may trigger cell apoptosis resulting in increased nucleic acid turnover and increased purine catabolism leading to an elevated plasma uric acid levels. The results obtained in the present studies in psoriasis patients shows a significant increase (p<0.001) in plasma uric acid levels as compared to the healthy normal control subjects (Table 2).

Since the day in 1958, Walkerin, first suggested that psoriasis may be associated with raised plasma uric acid levels, very few reports are available regarding the uric acid levels in psoriasis patients. Though the inter relationship between the uric acid levels and the severity of psoriasis been suggested but the study conducted in England negates such relationship. In the present study the psoriasis patients were divided into three groups depending on their PASI scores and it is observed that the plasma uric acid levels in psoriasis patients are significantly (p<0.001) elevated as compared to the normal healthy control subjects (Table 2). Further it is observed in the present study that the raise in plasma uric acid levels in psoriasis patients is quite comparable between the psoriasis groups studied. It is observed that there is a proportionate raise in plasma uric acid levels in Group-1, Group-2 and in Group-3 psoriasis patients suggesting a linearity raise with the severity of the disease which in agreement with the findings of Isha et al and Landert et al. It is evident from the results depicted in the Table 3 that the raise in plasma uric acid levels are significant (p<0.001) in both Groups-2 and 3 as compared to Group-1 and in Group-2 as compared to Group-1 (p<0.001) and in Group-3 as compared to Group-2 (p<0.001). Further it is evident from the results shown in Table 3 that the raise in plasma uric acid levels
in Group-1, Group- 2, Group-3 psoriasis patients is proportional to plasma cholesterol and plasma triacylglycerols levels suggesting that the raise observed in plasma uric acid levels in psoriasis is directly related to plasma lipid levels which in turn directly proportional to the severity of psoriasis disease as given by the PASI scores.

CONCLUSION

It can be concluded by the results obtained in the present study in psoriasis patients that the plasma uric acid levels are significantly elevated in psoriasis patients as compared to normal control subjects and the elevation in plasma uric acid levels is proportional to the severity of the disease as well as proportional to the elevated plasma lipid profile parameters. A parallel raise in plasma uric acid levels in relation to the severity of the psoriasis disease as evidenced by the present studies suggests the clinical usefulness of estimation of plasma uric acid levels in psoriasis patient to assess disease status. Anyhow more elaborate further research studies are needed with more number of patients with the detailed consideration of the psoriatic complications to establish clearly the exact relationship of psoriasis induced hyperuricemia with the elevated lipid profile parameters as well as the reason behind the raise of plasma uric acid levels in psoriasis patients.

ACKNOWLEDGEMENTS

The authors are indebted to the Management and Principal of Subbaiah Institute of Medical Sciences, Purale, Shamagga for their facilities support and encouragement.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the institutional ethics committee

REFERENCES

1. Seishima M, Seishima M, Mori S, Noma A. Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol. 1994;130(6):738-42.
2. Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Kremers HM. Trends in incidence of adult-onset psoriasis over three decades: a population-based study. J Am Acad Dermatol. 2009;60(3):394-401.
3. Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediators of inflammation. 2010;2010.
4. Chibrowska M. Role of serum lipid in psoriasis. Przegląd Dermatologiczny.1970;57(2):255-260
5. Pietrzak A, Toruniowa B, Pietrzak B, Chwaluk J. Lipid profile in psoriatic patients according to sex and age. Przegląd Dermatologiczny. 1994;81(5):441-9.
6. Pietrzak A, Jastrzębska I, Krasowska D, Chodorowska G, Tabarkiewicz J, Tomasiewicz K, et al. Serum pancreatic lipase [EC 3.1. 1.3] activity, serum lipid profile and peripheral blood dendritic cell populations in normolipidemic males with psoriasis. J Molecular Catalysis B: Enzymatic. 2006;40(3-4):144-54.
7. Mallbris L, Granath F, Hamsten A, Stähle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54(4):614-21.
8. Solak Tekin N, Tekin IO, Barut F, Yilmaz Sipahi E. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflammation. 2007;2007.
9. Farshchian M, Zamanian A, Farshchian M, Monsef AR, Mahjub H. Serum lipid level in Iranian patients with psoriasis. J Eur Acad Dermatol Venereol. 2007;21(6):802-5.
10. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Dermatol. 2007;157(1):68-73.
11. Cohen AD, Sherf M, Vidavsky L, Vardy DA, Shapiro J, Meyerovitch J. Association between psoriasis and the metabolic syndrome. Dermatology. 2008;216(2):152-5.
12. Tam LS, Tomlinson B, Chu TW, Li M, Leung YY, Kwok LW, Li TK, Yu T, Zhu YE, Wong KC, Kun EL.. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology. 2008;47(5):718-23.
13. Ferretti G, Simonetti O, Offidani AM, Messini L, Cinti B, Marshissepie I, Bossi G, Curatola G. Changes of plasma lipids and erythrocyte membrane fluidity in psoriatic children. Pediatric Res. 1993;33(5):506-9.
14. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dyslipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clinica Chimica Acta. 2001;303(1-2):33-9.
15. Akhyani M, Elsani AH, Robati RM, Robati AM. The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol. 2007;21(10):1330-2.
16. Javidi Z, Meibodi NT, Nahidi Y. Serum lipids abnormalities and psoriasis. Indian J Dermatol. 2007;52(2):89.
17. Amin T, Saied E, Abdou SH. Atherosclerotic risk in psoriasis. J Pan-Arab League Dermatologists. 2005;16(2):39-45.
18. Bajaj DR, Mahesar SM, Devrajani BR, Iqbal MP. Lipid profile in patients with psoriasis presenting at Liaquat University Hospital Hyderabad. JPMA. J Pakistan Med Association. 2009;59(8):512.
19. Reynoso-von Drateln C, Martínez-Abudinis E, Balcázar-Muñoz BR, Bustos-Saldaña R, González-Ortiz M. Lipid profile, insulin secretion, and insulin
sensitivity in psoriasis. J Am Acad Dermatol. 2003;48(6):882-5.
20. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41(6):1183-90.
21. Carnethon MR, Fortmann SP, Palaniappan L, Duncan BB, Schmidt MI, Chambless LE. Risk factors for progression to incident hyperinsulinemia: the Atherosclerosis Risk in Communities Study, 1987–1998. Am J Epidemiol. 2003;158(11):1058-67.
22. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, Tataru K. Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18(6):523-30.
23. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971-1992. JAMA. 2000;283(18):2404-10.
24. Prashanthkumar G, Nagendra S, Kashinath RT. Plasma Uric Acid Levels in Relation to Plasma Cholesterol Levels in Type-2 Diabetes Mellitus. Global J Med Res. 2015.
25. Lea Jr WA, Curtis AC, Bernstein IA. Serum Uric Acid Levels in Psoriasis1. J Investigative Dermatology. 1958;31(5):269-71.
26. Johnson RJ, Segal MS, Sautin Y, Nakagawa T, Feig DI, Kang DH, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007;86(4):899-906.
27. Johnson RJ, Titte S, Cade JR, Rideout BA, Oliver WJ. Uric acid, evolution and primitive cultures. InSeminars in nephrology. Elsevier. 2005;25(1):3-8.
28. Naito HK. In coronary artery disease and disorders of lipid metabolism: Clinical chemistry theory analysis co relations. 4th edition. In: Kaplan LA Peace AJ, Kazmierczak SC, Mosby, eds. St louis USA: 2003: 603.
29. Tietz NW. Clinical guide to laboratory tests, 3rd edition by Saunders Philadelphia USA), 1995: 610.
30. Matsuzaki Y, Kawaguchi E, Morita Y, Mashige F, Ohisa S, Nakahara K. Evaluation of two kinds of reagents for direct determination of HDL-cholesterol. J Anal Bio-Sc. 1996;19:419-27.
31. Tietz NW. Clinical guide to laboratory tests. 3rd edition. Philadelphia, USA: Saunders; 1995: 624.
32. Kumari A, Gowda H. A clinical study of psoriasis and its association with serum lipid profile. J Evolution Med Dent Sci. 2017;6(23):1898-904.
33. Piskin S, Gurkok F, EKuku G, Senol M. Serum lipid levels in psoriasis. Yonsei Med J. 2003;44(1):24-6.
34. Örem A, Çimidt G, Değer O, Örem C, Vanizor B. The significance of autoantibodies against oxidatively modified low-density lipoprotein (LDL) in patients with psoriasis. Clinica Chimica Acta. 19995;284(1):81-8.
35. Kural BV, Örem A, Çimidt G, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant–antioxidant system in patients with psoriasis. Clinica Chimica Acta. 2003;328(1-2):71-82.
36. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, Figueiredo A, Teixeira F, Castro E, Rocha-Pereira P, Santos-Silva A. Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease. J Dermatological Sci. 2009;55(3):202-4.
37. Im SS, Yusof L, Blaschitz C, Liu JZ, Edwards RA, Young SG, Raffatellu M, Osborne TF. Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metabolism. 2011;13(5):540-9.
38. Chakrabarti R, Engleman EG. Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. J Biological Chem. 1991;266(19):12216-22.
39. Getz GS, Reardon CA. The mutual interplay of lipid metabolism and the cells of the immune system in relation to atherosclerosis. Clin Lipidol. 2014;9(6):657-71.
40. Wu X, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominid evolution. J Molecular Evolution. 1992;34(1):78-84.
41. Glantzounis GK, Tsimosyiannis EC, Kappas AM, Galaris DA. Uric acid and oxidative stress. Current Pharmaceutical Design. 2005;11(32):4145-51.
42. Eisen AZ, Seegmiller JE. Uric acid metabolism in psoriasis. J Clin Investigation. 1961;40(8):1486-94.
43. Scott JT, Stedell MA. Serum uric acid levels in psoriasis. In: Purine Metabolism in Man-IV. Boston, MA: Springer; 1984: 283-285.
44. Jain VK, Lal H. C-reactive protein and uric acid levels in patients with psoriasis. Indian J Clin Biochem. 2011;26(3):309-11.
45. Lambert JR, Wright V. Serum uric acid levels in psoriatic arthritis. Annals Rheumatic Dis. 1977;36(3):264-7.

Cite this article as: Srinivas S, Goudappala P, Kashinath RT. Inter relationship of plasma lipid profile parameters with plasma uric acid levels in psoriasis. Int J Res Dermatol 2018;4:318-22.